RATES OF MELANOMA HAVE BEEN ON THE RISE FOR 30 YEARS
WHAT NEW RESEARCH AND TREATMENT APPROACHES MAY IMPACT THE MELANOMA COMMUNITY?
New findings in Immuno-Oncology will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting in New Orleans in regard to advanced melanoma. Immuno-Oncology is an innovative field of cancer research, which may lead to treatments that can help the body’s immune system attack melanoma cells more effectively. Experts at the forefront of cancer research are exploring ways to work directly with the body’s immune system to fight cancers like metastatic melanoma.
Metastatic melanoma is the deadliest form of melanoma, which is a form of skin cancer characterized by the uncontrolled growth of pigment-producing cells located in the skin1. The incidence of melanoma has been increasing for at least 30 years, with an estimated 76,380 melanoma cases expected to be diagnosed in the U.S. in 20161.
Steven J. O’Day, MD, Co-Director of Melanoma Program, Melanoma Specialist, Professor of Medical Oncology, Director of Immuno-Oncology, Director of Clinical Research, John Wayne Cancer Institute at Providence Saint John’s Health Center Santa Monica CA, will be available to update your viewers/listeners on the latest news in the fight against melanoma and the burden of this disease.
WHY HAS METASTATIC MELANOMA BEEN SUCH A DIFFICULT DISEASE TO DIAGNOSE AND TREAT? HOW COMMON IS MELANOMA, AND WHAT ARE CURRENT INCIDENCE RATES? WHAT IS IMMUNO-ONCOLOGY AND HOW IS IT DIFFERENT FROM OTHER CURRENT MELANOMA TREATMENTS. NEW DATA ON IMMUNO-ONCOLOGY IN MELANOMA WAS RECENTLY PRESENTED AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH ANNUAL MEETING. WHAT DOES THIS DATA MEAN FOR THE MELANOMA COMMUNITY? WHAT SHOULD PEOPLE WITH MELANOMA, AND/OR THEIR FAMILIES DO TO LEARN MORE ABOUT IMMUNO-ONCOLOGY OR THEIR TREATMENT OPTIONS?